In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis

References

• Effah CY, Sun T, Liu S, et al. Klebsiella pneumoniae: an increasing threat to public health. Ann Clin Microbiol Antimicrob. 2020 Jan 9;19(1):1. doi:10.1186/s12941-019-0343-8
   PubMed Web of Science ®Google Scholar
• Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017 Mar 29;16(1):18. doi:10.1186/s12941-017-0191-3
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013 Sep;13(9):785–796. doi:10.1016/S1473-3099(13)70190-7
   PubMed Web of Science ®Google Scholar
• Bush K. Past and Present Perspectives on β-Lactamases. Antimicrob Agents Chemother. 2018 Oct;62(10):e01076-18. doi:10.1128/AAC.01076-18
   PubMed Web of Science ®Google Scholar
• Wang Q, Wang X, Wang J, et al. Phenotypic and genotypic characterization of carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE Study in China (2012-2016). Clin Infect Dis. 2018 Nov 13;67(suppl_2):S196–s205. doi:10.1093/cid/ciy660
   PubMedGoogle Scholar
• Munoz-Price LS, Quinn JP. The spread of Klebsiella pneumoniae carbapenemases: a tale of strains, plasmids, and transposons. Clin Infect Dis. 2009 Dec 1;49(11):1739–1741. doi:10.1086/648078
   PubMed Web of Science ®Google Scholar
• Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother. 2009 Aug;53(8):3365–3370. doi:10.1128/AAC.00126-09
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Lev B, Israeli A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011 Apr 1;52(7):848–855. doi:10.1093/cid/cir025
   PubMed Web of Science ®Google Scholar
• Warburg G, Hidalgo-Grass C, Partridge SR, et al. A carbapenem-resistant Klebsiella pneumoniae epidemic clone in Jerusalem: sequence type 512 carrying a plasmid encoding aac(6’)-Ib. J Antimicrob Chemother. 2012 Apr;67(4):898–901. doi:10.1093/jac/dkr552
   PubMed Web of Science ®Google Scholar
• Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013 Jan;19(1):E23–e30. doi:10.1111/1469-0691.12070
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019 Jan 18;68(3):355–364. doi:10.1093/cid/ciy492
   PubMed Web of Science ®Google Scholar
• Aitken SL, Tarrand JJ, Deshpande LM, et al. High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-β-lactamase production in enterobacteriaceae bloodstream infections at a Major Cancer Center. Clin Infect Dis. 2016 Oct 1;63(7):954–958. doi:10.1093/cid/ciw398
   PubMed Web of Science ®Google Scholar
• Ding L, Shen S, Chen J, et al. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clin Microbiol Rev. 2023 Dec 20;36(4):e0000823. doi:10.1128/cmr.00008-23
   PubMed Web of Science ®Google Scholar
• Di Pilato V, Principe L, Andriani L, et al. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam. Clin Microbiol Infect. 2023 Apr;29(4):537.e1–537.e8. doi:10.1016/j.cmi.2022.11.011
   PubMed Web of Science ®Google Scholar
• Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne bla(KPC-3) mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017 Mar;61(3):e02097-16. doi:10.1128/AAC.02097-16
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Press EG, et al. Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing k pneumoniae: a case report and review of literature. Open Forum Infect Dis. 2017 Summer;4(3):ofx101. doi:10.1093/ofid/ofx101
   PubMed Web of Science ®Google Scholar
• Gaibani P, Campoli C, Lewis RE, et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother. 2018 Jun 1;73(6):1525–1529. doi:10.1093/jac/dky082
   PubMed Web of Science ®Google Scholar
• Giddins MJ, Macesic N, Annavajhala MK, et al. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in bla(KPC-2)-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. 2018 Mar;62(3):e01111-19. doi:10.1128/AAC.02101-17
   Web of Science ®Google Scholar
• Di Pilato V, Aiezza N, Viaggi V, et al. KPC-53, a KPC-3 variant of clinical origin associated with reduced susceptibility to ceftazidime-avibactam. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01429-20. doi:10.1128/AAC.01429-20
   PubMed Web of Science ®Google Scholar
• Shi Q, Yin D, Han R, et al. Emergence and recovery of ceftazidime-avibactam resistance in blakpc-33-harboring Klebsiella pneumoniae sequence type 11 isolates in China. Clin Infect Dis. 2020 Dec 23;71(Suppl 4):S436–s439. doi:10.1093/cid/ciaa1521
   PubMedGoogle Scholar
• Galani I, Karaiskos I, Angelidis E, et al. Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment. Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):219–224. doi:10.1007/s10096-020-04000-9
   PubMed Web of Science ®Google Scholar
• Hernández-García M, Sánchez-López J, Martínez-García L, et al. Emergence of the new KPC-49 variant conferring an ESBL phenotype with resistance to ceftazidime-avibactam in the ST131-H30R1 Escherichia coli high-risk clone. Pathogens. 2021 Jan 14;10(1):67. doi:10.3390/pathogens10010067
   PubMed Web of Science ®Google Scholar
• Tiseo G, Falcone M, Leonildi A, et al. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae-producing KPC-31, a D179Y variant of KPC-3. Open Forum Infect Dis. 2021 Jun;8(6):ofab141. doi:10.1093/ofid/ofab141
   PubMed Web of Science ®Google Scholar
• Wang C, Zhao J, Liu Z, et al. In vivo selection of imipenem resistance among ceftazidime-avibactam-resistant, imipenem-susceptible Klebsiella pneumoniae isolate with KPC-33 carbapenemase. Front Microbiol. 2021;12:727946. doi:10.3389/fmicb.2021.727946
   PubMed Web of Science ®Google Scholar
• Arcari G, Oliva A, Sacco F, et al. Interplay between Klebsiella pneumoniae producing KPC-31 and KPC-3 under treatment with high dosage meropenem: a case report. Eur J Clin Microbiol Infect Dis. 2022 Mar;41(3):495–500. doi:10.1007/s10096-021-04388-y
   PubMed Web of Science ®Google Scholar
• Ding L, Shen S, Han R, et al. Ceftazidime-avibactam in combination with imipenem as salvage therapy for ST11 KPC-33-producing Klebsiella pneumoniae. Antibiotics (Basel). 2022 Apr 29;11(5):604.
   PubMed Web of Science ®Google Scholar
• Muresu N, Del Rio A, Fox V, et al. Genomic characterization of KPC-31 and OXA-181 Klebsiella pneumoniae resistant to new generation of β-Lactam/β-Lactamase inhibitor combinations. Antibiotics (Basel). 2022 Dec 21;12(1):10.
   PubMed Web of Science ®Google Scholar
• Di Pilato V, Codda G, Niccolai C, et al. Functional features of KPC-109, a novel 270-loop KPC-3 mutant mediating resistance to avibactam-based β-lactamase inhibitor combinations and cefiderocol. Int J Antimicrob Agents. 2024 Jan;63(1):107030. doi:10.1016/j.ijantimicag.2023.107030
   PubMed Web of Science ®Google Scholar
• Mueller L, Masseron A, Prod’Hom G, et al. Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity. Antimicrob Agents Chemother. 2019 Sep 9;63(12):e02097-16. doi:10.1128/AAC.01111-19
   Web of Science ®Google Scholar
• Jiang M, Sun B, Huang Y, et al. Diversity of ceftazidime-avibactam resistance mechanism in KPC2-producing Klebsiella pneumoniae under antibiotic selection pressure. Infect Drug Resist. 2022;15:4627–4636. doi:10.2147/IDR.S371285
   PubMed Web of Science ®Google Scholar
• Ding L, Shi Q, Han R, et al. Comparison of four carbapenemase detection methods for bla(KPC-2) variants. Microbiol Spectr. 2021 Dec 22;9(3):e0095421. doi:10.1128/Spectrum.00954-21
   PubMed Web of Science ®Google Scholar
• Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001 Apr;45(4):1151–1161. doi:10.1128/AAC.45.4.1151-1161.2001
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Lob SH, DeRyke CA, et al. In Vitro activity of Ceftolozane-tazobactam, imipenem-relebactam, ceftazidime-avibactam, and comparators against Pseudomonas aeruginosa isolates collected in United States hospitals according to results from the SMART Surveillance Program, 2018 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0018922. doi:10.1128/aac.00189-22
   PubMed Web of Science ®Google Scholar
• Sy SKB, Zhuang L, Sy S, et al. Clinical pharmacokinetics and pharmacodynamics of ceftazidime-avibactam combination: a model-informed strategy for its clinical development. Clin Pharmacokinet. 2019 May;58(5):545–564. doi:10.1007/s40262-018-0705-y
   PubMed Web of Science ®Google Scholar
• Liu C, Wu Y, Huang L, et al. The rapid emergence of ceftazidime-avibactam resistance mediated by KPC variants in carbapenem-resistant Klebsiella pneumoniae in Zhejiang Province, China. Antibiotics (Basel). 2022 May 30;11(6):731.
   PubMed Web of Science ®Google Scholar
• Hobson CA, Pierrat G, Tenaillon O, et al. Klebsiella pneumoniae carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0044722. doi:10.1128/aac.00447-22
   PubMed Web of Science ®Google Scholar
• Li X, Zhang J, Yang C, et al. Increased expression and amplification of bla(KPC-2) contributes to resistance to ceftazidime/avibactam in a sequence Type 11 carbapenem-resistant Klebsiella pneumoniae strain. Microbiol Spectr. 2022 Aug 31;10(4):e0095522.
   PubMed Web of Science ®Google Scholar
• Wong JLC, Romano M, Kerry LE, et al. OmpK36-mediated carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo. Nat Commun. 2019 Sep 2;10(1):3957. doi:10.1038/s41467-019-11756-y
   PubMedGoogle Scholar
• Lombardo D, Ambretti S, Lazzarotto T, et al. In vitro activity of imipenem-relebactam against KPC-producing Klebsiella pneumoniae resistant to ceftazidime-avibactam and/or meropenem-vaborbactam. Clin Microbiol Infect. 2022 May;28(5):749–751. doi:10.1016/j.cmi.2022.01.025
   PubMed Web of Science ®Google Scholar
• Findlay J, Poirel L, Nordmann P. In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates. J Glob Antimicrob Resist. 2023 Mar;32:66–71. doi:10.1016/j.jgar.2022.12.009
   PubMed Web of Science ®Google Scholar
• Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev. 2006 Apr;19(2):382–402. doi:10.1128/CMR.19.2.382-402.2006
   PubMed Web of Science ®Google Scholar
• Gato E, Guijarro-Sánchez P, Alonso-García I, et al. In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification. Int J Antimicrob Agents. 2023 Oct;62(4):106935. doi:10.1016/j.ijantimicag.2023.106935
   PubMed Web of Science ®Google Scholar
• Lee YL, Ko WC, Hsueh PR. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106679. doi:10.1016/j.ijantimicag.2022.106679
   PubMed Web of Science ®Google Scholar
• Del Rio A, Fox V, Muresu N, et al. A whole-genome sequencing-based approach for the characterization of Klebsiella pneumoniae co-producing KPC and OXA-48-like carbapenemases circulating in Sardinia, Italy. Microorganisms. 2023 Sep 20;11(9):2354. doi:10.3390/microorganisms11092354
   PubMed Web of Science ®Google Scholar
• Yu M, Wei Q, Song W, et al. Phenotypic and genetic analysis of KPC-49, a KPC-2 variant conferring resistance to ceftazidime-avibactam and maintaining resistance to imipenem and meropenem. Infect Drug Resist. 2023;16:2477–2485. doi:10.2147/IDR.S406319
   PubMed Web of Science ®Google Scholar
• Tam VH, Merlau PR, Hudson CS, et al. Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 Oct 28;77(11):3130–3137. doi:10.1093/jac/dkac294
   PubMed Web of Science ®Google Scholar
• Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S565–s575. doi:10.1093/cid/ciz830
   PubMed Web of Science ®Google Scholar
• Zhen S, Wang H, Feng S. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections. Infection. 2022 Dec;50(6):1409–1423. doi:10.1007/s15010-022-01876-x
   PubMed Web of Science ®Google Scholar
• Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/avibactam, meropenem/vaborbactam, or both? Clinical and formulary considerations. Clin Infect Dis. 2019 Jan 18;68(3):519–524. doi:10.1093/cid/ciy576
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother. 2018 May;62(5):e02497-17. doi:10.1128/AAC.02497-17
   PubMed Web of Science ®Google Scholar
• Louie A, Castanheira M, Liu W, et al. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Antimicrob Agents Chemother. 2012 Jan;56(1):258–270. doi:10.1128/AAC.05005-11
   PubMed Web of Science ®Google Scholar
• Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop. J Antimicrob Chemother. 2015 Aug;70(8):2279–2286. doi:10.1093/jac/dkv094
   PubMed Web of Science ®Google Scholar
• Bassetti M, Carannante N, Pallotto C, et al. KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: a retrospective observational study. J Glob Antimicrob Resist. 2019 Jun;17:109–111. doi:10.1016/j.jgar.2018.11.014
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-avibactam use for klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a Retrospective Observational Multicenter Study. Clin Infect Dis. 2021 Nov 2;73(9):1664–1676. doi:10.1093/cid/ciab176
   PubMed Web of Science ®Google Scholar
• Sun D, Rubio-Aparicio D, Nelson K, et al. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017 Dec;61(12):e01694-17.
   PubMed Web of Science ®Google Scholar
• Balabanian G, Rose M, Manning N, et al. Effect of porins and bla(KPC) expression on activity of imipenem with relebactam in Klebsiella pneumoniae: can antibiotic combinations overcome resistance? Microb Drug Resist. 2018 Sep;24(7):877–881. doi:10.1089/mdr.2018.0065
   PubMed Web of Science ®Google Scholar
• Haidar G, Clancy CJ, Chen L, et al. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant enterobacteriaceae. Antimicrob Agents Chemother. 2017 Sep;61(9):e00642-17. doi:10.1128/AAC.00642-17
   PubMed Web of Science ®Google Scholar